Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000489879 | SCV000576865 | uncertain significance | not provided | 2017-04-17 | criteria provided, single submitter | clinical testing | The I576T variant in the SMARCAL1 gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. The I576T variant is observed in 14/10400 (0.13%) alleles from individuals of African background, in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The I576T variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position where amino acids with similar properties to Isoleucine are tolerated across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. We interpret I576T as a variant of uncertain significance. |
Labcorp Genetics |
RCV000814798 | SCV000955225 | likely benign | Schimke immuno-osseous dysplasia | 2023-12-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002526018 | SCV003531477 | uncertain significance | Inborn genetic diseases | 2024-01-09 | criteria provided, single submitter | clinical testing | The c.1727T>C (p.I576T) alteration is located in exon 11 (coding exon 9) of the SMARCAL1 gene. This alteration results from a T to C substitution at nucleotide position 1727, causing the isoleucine (I) at amino acid position 576 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000814798 | SCV002076312 | uncertain significance | Schimke immuno-osseous dysplasia | 2019-11-11 | no assertion criteria provided | clinical testing |